# Cannabis Regulatory Updates March 2026: Key Policy Watch

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabis-regulatory-updates-march-2026/
> **Published:** 2026-03-12T08:51:19-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:08:50-04:00
> **Clinical Summary:** Stay informed with cannabis regulatory updates March 2026 covering federal scheduling, Medicare policies, and clinical implications for cannabis medicine.

---

Policy WatchMarch 12, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.

Score 70Regulations.gov

[Schedules of Controlled Substances: Rescheduling of Marijuana](https://www.regulations.gov/document/DEA-2024-0059-0001)

Regulatory Summary

The rescheduling of marijuana under controlled substance schedules directly affects cannabis clinicians’ prescribing authority, patient access to treatment, and research capabilities by altering legal classification and regulatory requirements.

[Read more →](https://www.regulations.gov/document/DEA-2024-0059-0001)

Score 70Regulations.gov
[Definition of Engaged in the Business as a Dealer in Firearms](https://www.regulations.gov/document/ATF_FRDOC_0001-0052)

This firearms regulation defines dealer licensing requirements and has no direct relevance to cannabis clinicians or patients, as it pertains exclusively to firearms commerce and does not intersect with [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice or patient care.

[Read more →](https://www.regulations.gov/document/ATF_FRDOC_0001-0052)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0006)

This DEA action schedules three synthetic opioids as Schedule I controlled substances, with no direct relevance to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice or patient treatment protocols.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0006)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0007)

Regulatory Action Summary

This DEA action schedules three synthetic opioids (butonitazene, flunitazene, metodesnitazene) as controlled substances, with no direct relevance to cannabis medicine practice or patient care.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0007)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I](https://www.regulations.gov/document/DEA-2024-0026-0001)

Regulatory Summary

The DEA placed 2-Methyl AP-237, a synthetic opioid analog, into Schedule I, establishing maximum criminal penalties; this action does not directly affect cannabis clinical practice or patient access.

[Read more →](https://www.regulations.gov/document/DEA-2024-0026-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I](https://www.regulations.gov/document/DEA-2023-0168-0001)

This regulatory action schedules synthetic amphetamines (DOI and DOC), not cannabis, and has no direct relevance to cannabis clinicians or patients.

[Read more →](https://www.regulations.gov/document/DEA-2023-0168-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I](https://www.regulations.gov/document/DEA-2023-0049-0004)

Regulatory Summary

The DEA temporarily placed six synthetic cannabinoids into Schedule I, restricting their legal availability and potentially affecting patients relying on unregulated cannabinoid products for therapeutic purposes.

[Read more →](https://www.regulations.gov/document/DEA-2023-0049-0004)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0001)

Regulatory Summary

This DEA action schedules ethylphenidate (a stimulant metabolite) as a controlled substance, establishing regulatory precedent for classifying novel psychoactive compounds—potentially informing how cannabis-derived cannabinoids and synthetic analogs are evaluated.

[Read more →](https://www.regulations.gov/document/DEA-2023-0129-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Metonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0005)

Regulatory Summary

The DEA placed metonitazene, a synthetic opioid, into Schedule I, restricting its availability; this action does not directly affect cannabis clinical practice or patient access.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0005)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I](https://www.regulations.gov/document/DEA-2022-0145-0004)

Regulatory Summary

The DEA temporarily placed five benzodiazepine analogues into Schedule I, restricting their legal availability—relevant to cannabis clinicians managing anxiety and sleep disorders who may have considered these as adjunctive treatments.

[Read more →](https://www.regulations.gov/document/DEA-2022-0145-0004)

Score 70Regulations.gov
[Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224](https://www.regulations.gov/document/DEA-2023-0096-0001)

Regulatory Summary

A biopharmaceutical research company applied to become a DEA-registered importer of controlled substances, potentially enabling [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and patient access to cannabis-derived pharmaceutical products under federal oversight.

[Read more →](https://www.regulations.gov/document/DEA-2023-0096-0001)

Score 55Regulations.gov
[Importer of Controlled-Bright Green(2024-20083)DEA1426](https://www.regulations.gov/document/DEA-2024-0111-0001)

Regulatory Summary

DEA registration document (2024-20083) authorizes importation of controlled substances; clinicians and patients should verify their medication source’s legitimate DEA import licensing status.

[Read more →](https://www.regulations.gov/document/DEA-2024-0111-0001)

Score 55Regulations.gov
[Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429](https://www.regulations.gov/document/DEA-2024-0110-0001)

Regulatory Summary

DEA registration for Cambridge Isotope as a controlled substance importer enables sourcing of isotopically-labeled research compounds for [cannabis pharmacology](https://cedclinic.com/cannabis-tolerance-behavioral-models/) studies, supporting [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and drug development.

[Read more →](https://www.regulations.gov/document/DEA-2024-0110-0001)

Score 55Regulations.gov
[Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.](https://www.regulations.gov/document/CMS-2024-0256-0045)

CMS updated 2025 physician payment policies and Part B coverage determinations, potentially affecting cannabis clinician reimbursement rates and patient access to cannabis-related medical services under Medicare and Medicaid programs.

[Read more →](https://www.regulations.gov/document/CMS-2024-0256-0045)

Score 55Regulations.gov
[Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)](https://www.regulations.gov/document/CMS-2024-0256-0001)

Regulatory Summary

This proposed rule updates Medicare/Medicaid payment policies and coverage rules for 2025, potentially affecting reimbursement and clinical practice standards for cannabis-related medical services under federal healthcare programs.

[Read more →](https://www.regulations.gov/document/CMS-2024-0256-0001)

Score 55Regulations.gov
[Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368](https://www.regulations.gov/document/DEA-2024-0060-0001)

Regulatory Summary

DEA approval of Royal Emerald as a bulk cannabis manufacturer expands licensed production capacity, potentially increasing medicine availability and supply chain options for cannabis clinicians and patients.

[Read more →](https://www.regulations.gov/document/DEA-2024-0060-0001)

Score 55Regulations.gov
[Importer Controlled-VA Cooperative (2024-11795) DEA1374](https://www.regulations.gov/document/DEA-2024-0064-0001)

Regulatory Summary

DEA Form 1374 governs importer licenses for controlled substances; this 2024 cooperative agreement affects cannabis clinicians’ and patients’ access to federally regulated cannabis products through licensed importers.

[Read more →](https://www.regulations.gov/document/DEA-2024-0064-0001)

Score 55Regulations.gov
[Importer Controlled- Quagen Pharma (2024-11892) DEA1381](https://www.regulations.gov/document/DEA-2024-0070-0001)

Regulatory Summary

DEA Import Control Action 2024-11892 against Quagen Pharma restricts controlled substance importation, potentially affecting cannabis clinicians’ and patients’ access to pharmaceutical cannabinoid products and related medicines.

[Read more →](https://www.regulations.gov/document/DEA-2024-0070-0001)

Score 55Regulations.gov
[Exempt Chemical Preparations May 2024 (2024-10465) – DEA372](https://www.regulations.gov/document/DEA-2022-0002-0006)

Regulatory Summary

The DEA’s May 2024 guidance on exempt chemical preparations clarifies which cannabis-derived products are exempt from Schedule I controls, affecting prescribing eligibility and patient access to certain cannabinoid formulations.

[Read more →](https://www.regulations.gov/document/DEA-2022-0002-0006)

Score 55Regulations.gov
[Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-F)](https://www.regulations.gov/document/CMS-2023-0121-22025)

This CMS final rule establishes 2024 Medicare/Medicaid payment policies and coverage requirements; cannabis remains federally non-covered, limiting patient access and clinician reimbursement under these programs.

[Read more →](https://www.regulations.gov/document/CMS-2023-0121-22025)

Digest-Level Clinical Commentary

 Dr. Caplan’s Take
 Clinical Reflection

The predominance of synthetic cannabinoid and novel psychoactive substance scheduling in this digest, combined with the absence of substantive cannabis rescheduling implementation guidance, reflects the current regulatory reality that practitioners like myself operate within a fragmented framework where cannabis remains federally scheduled despite growing clinical evidence and state-level legalization. The concurrent focus on Medicare/Medicaid reimbursement policies suggests we should anticipate that insurance coverage questions will increasingly outpace the clinical guidance currently available for cannabis-based therapeutics. What these items collectively signal is that cannabis medicine practitioners must remain vigilant about distinguishing evidence-based cannabinoid therapeutics from uncontrolled synthetic analogs while simultaneously preparing for the administrative and billing complexities that will accompany any shifts in federal coverage policies.

 Clinical Perspective

Clinical Perspective

These regulatory items reflect the ongoing evolution of controlled substance scheduling, with particular attention to emerging synthetic drugs and new chemical variants that continue to challenge public health authorities. The inclusion of multiple synthetic opioids and benzodiazepine analogues suggests a persistent pattern of clandestine drug manufacturing designed to circumvent existing regulations, requiring continuous monitoring and scheduling updates. The cannabis rescheduling consideration alongside these actions indicates a broader reassessment of drug classification frameworks, while concurrent Medicare policy updates highlight the healthcare system’s need to adapt reimbursement structures as medication access and prescribing patterns continue to change.

Controlled Substances SchedulingDrug EnforcementCannabis Regulation[Healthcare Policy](https://cedclinic.com/cannabis-legalization-in-canada-new-opportunities/)Federal Rulemaking

💬 Join the Conversation

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+March+12%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+March+12%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)

 Related Articles

- [Regulatory Digest 2026-03-06](https://cedclinic.com/regulatory-digest-2026-03-09/)

- [Regulatory Digest 2026-03-06](https://cedclinic.com/controlled-substances-rescheduling-2026/)

- [Regulatory Digest 2026-03-05](https://cedclinic.com/regulatory-cannabis-manufacturing-compliance-2026/)

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[Policy Watch: 20 Regulatory Updates — March 14, 2026](https://cedclinic.com/dea-marijuana-schedule-change-2026-regulatory-update/)

Explore the latest regulatory changes affecting cannabis medicine just two days after the March 12 update. Understand evolving policies and their clinical impact.

[Read More](https://cedclinic.com/dea-marijuana-schedule-change-2026-regulatory-update/)

[Policy Watch: 27 Regulatory Updates — March 16, 2026](https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/)

A comprehensive review of 27 regulatory updates in mid-March 2026, providing deeper insights into federal cannabis scheduling and [healthcare policy](https://cedclinic.com/cannabis-legalization-in-canada-new-opportunities/) shifts.

[Explore Updates](https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/)

[Policy Watch: 10 Regulatory Updates — March 19, 2026](https://cedclinic.com/dea-synthetic-opioid-scheduling-updates-march-2026/)

Stay current with 10 key regulatory updates from late March 2026, focusing on cannabis policy and clinical practice implications.

[Learn More](https://cedclinic.com/dea-synthetic-opioid-scheduling-updates-march-2026/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).